Drug Development Pharma - March 12, 2014
AstraZeneca sells Alderley Park site in Cheshire
AstraZeneca is selling its Alderley Park site in Cheshire, UK, to Manchester Science Parks. Manchester Science Parks (MSP) is a Manchester-based public-private partnership and science park operator. Chris Oglesby, Chairman of MSP and Chief Executive of MSP majority shareholder, Bruntwood, commented in a statement: “We are delighted to have been entrusted with securing the future of Alderley […]
Agreement - March 12, 2014
Biogaia enters extended agreement with Nestlé
Nestlé and BioGaia have entered into a supplementary agreement to the original from February 2012 when Biogaia sold the rights for the use of Lactobacillus reuteri Protectis in infant formula to Nestle. Under the original agreement in 2012, Biogaia received EUR 40 million up-front as well as a commitment to a further EUR 10.8 million between […]
Uncategorized - March 11, 2014
Sugar test can reduce false-positive cancer diagnosis
Chemists at the University of Copenhagen have developed a method able to halve the number of false-positives ovarian cancer diagnoses. The method helps distinguish between cancer and otherwise benign conditions and is called glycoprofiling. It has been published in the Journal of Proteome Research, under the title “Microarray Glycoprofiling of CA125 Improves Differential Diagnosis of Ovarian […]
Uncategorized - March 11, 2014
Great Britain to finance ESS
Recently it was announced that Spain is contributing with finances to the building of European Spallation Source in Lund and on March 11 it was announced that Great Britain will contribute with EUR 195 million. The sum is equivalent of SEK 1.8 billion and 10 percent of the total cost. “That the British government is chosing to […]
Uncategorized - March 11, 2014
Cellular mechanism represses immune reaction in type I-diabetes
According to a new study by researchers from Karolinska Institutet and University of Miami Miller School of Medicine, direct contact between different types of immune cells protects tissues from being attacked by the immune defence. In type I diabetes, immune cells kill insulin-producing beta cells in the pancreas. It remains largely unknown how target tissue is […]
Collaboration - March 7, 2014
Sectra and IDS to collaborate in mammography
The two companies brings Sectra CloudFlex, a cloud-based, comprehensive suite of breast imaging tools designed for low-volume mammography sites. The tools’ modular functionality includes a clinical reporting platform, advanced speech recognition technology, a workflow portal and CRM system. This synergistic collaboration with IDS allows Sectra to expand its women’s health portfolio into small breast centers […]
